Ross Cagan
YOU?
Author Swipe
View article: WNT signalling promotes NF-κB activation and drug resistance in KRAS-mutant colorectal cancer
WNT signalling promotes NF-κB activation and drug resistance in KRAS-mutant colorectal cancer Open
Approximately 40% of colorectal cancer (CRC) cases are characterised by KRAS mutations, rendering them insensitive to most therapies. While the reasons for this resistance remain incompletely understood, one key aspect is genetic complexit…
View article: Colon cancer cells evade drug action by enhancing drug metabolism
Colon cancer cells evade drug action by enhancing drug metabolism Open
Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide. One key reason is the lack of durable therapies that target KRAS-dependent disease, which represents approximately 40% of CRC cases. Here, we use liquid chroma…
View article: Rigosertib Reverses Hypertrophic Cardiomyopathy in<i>RAF1</i>-Associated Noonan Syndrome
Rigosertib Reverses Hypertrophic Cardiomyopathy in<i>RAF1</i>-Associated Noonan Syndrome Open
Background RASopathies constitute a group of rare genetic disorders caused by mutations in genes that reside along the canonical Ras/MAPK signaling pathway, affecting cell growth and differentiation. These syndromes, which include conditio…
View article: Functional exploration of copy number alterations in a <i>Drosophila</i> model of triple-negative breast cancer
Functional exploration of copy number alterations in a <i>Drosophila</i> model of triple-negative breast cancer Open
Accounting for 10-20% of breast cancer cases, triple-negative breast cancer (TNBC) is associated with a disproportionate number of breast cancer deaths. One challenge in studying TNBC is its genomic profile: with the exception of TP53 loss…
View article: Flow zoometry of<i>Drosophila</i>
Flow zoometry of<i>Drosophila</i> Open
Drosophila serves as a highly valuable model organism across numerous fields including genetics, immunology, neuroscience, cancer biology, and developmental biology. Central to Drosophila -based biological research is the ability to perfor…
View article: Cell competition and cancer from Drosophila to mammals
Cell competition and cancer from Drosophila to mammals Open
Throughout an individual’s life, somatic cells acquire cancer-associated mutations. A fraction of these mutations trigger tumour formation, a phenomenon partly driven by the interplay of mutant and wild-type cell clones competing for domin…
View article: WNT Signalling Promotes NF-κB Activation and Drug Resistance in KRAS-Mutant Colorectal Cancer
WNT Signalling Promotes NF-κB Activation and Drug Resistance in KRAS-Mutant Colorectal Cancer Open
Approximately 40% of colorectal cancer (CRC) cases are characterized by KRAS mutations, rendering them insensitive to most CRC therapies. While the reasons for this resistance remain incompletely understood, one key aspect is genetic compl…
View article: Colon Cancer Cells Evade Drug Action by Enhancing Drug Metabolism
Colon Cancer Cells Evade Drug Action by Enhancing Drug Metabolism Open
Colorectal cancer (CRC) is the second most deadly cancer worldwide. One key reason is the failure of therapies that target RAS proteins, which represent approximately 40% of CRC cases. Despite the recent discovery of multiple alternative s…
View article: A polycistronic transgene design for combinatorial genetic perturbations from a single transcript in Drosophila
A polycistronic transgene design for combinatorial genetic perturbations from a single transcript in Drosophila Open
Experimental models that capture the genetic complexity of human disease and allow mechanistic explorations of the underlying cell, tissue, and organ interactions are crucial to furthering our understanding of disease biology. Such models …
View article: Table S1 and S2 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Table S1 and S2 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
Shows statistics for drug screen in flies and CI index in human cell lines
View article: Data from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Data from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
A key tool of cancer therapy has been targeted inhibition of oncogene-addicted pathways. However, efficacy has been limited by progressive emergence of resistance as transformed cells adapt. Here, we use Drosophila to dissect response to t…
View article: Figure S6 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Figure S6 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
Figure S6, shows effect of different 'network brake' drug combinations on wildtype flies
View article: Figure S7&S8 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Figure S7&S8 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
Figure S7, S8, shows effect of sorafenib/bortezomib/vorinostat on TT cell tumor xenografts in mice and effect of 'network brake' drug combinations on different human cancer cells
View article: Figure S9 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Figure S9 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
Figure S9 shows 'network brake drugs' affects Sox2 in thyroid cells; have little effect in the absence of targeted therapy
View article: Table S1 and S2 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Table S1 and S2 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
Shows statistics for drug screen in flies and CI index in human cell lines
View article: Figure S9 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Figure S9 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
Figure S9 shows 'network brake drugs' affects Sox2 in thyroid cells; have little effect in the absence of targeted therapy
View article: Data from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Data from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
A key tool of cancer therapy has been targeted inhibition of oncogene-addicted pathways. However, efficacy has been limited by progressive emergence of resistance as transformed cells adapt. Here, we use Drosophila to dissect response to t…
View article: Figure S7&S8 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Figure S7&S8 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
Figure S7, S8, shows effect of sorafenib/bortezomib/vorinostat on TT cell tumor xenografts in mice and effect of 'network brake' drug combinations on different human cancer cells
View article: Figure S4&S5 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Figure S4&S5 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
Figure S4, S5, shows drug combinations that restrain or hyperactivate different cellular pathways in flies
View article: Figure S2&S3 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Figure S2&S3 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
Figure S2, S3, shows effect of different doses of sorafenib on wing phenotype and cellular pathways in flies
View article: Figure S6 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Figure S6 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
Figure S6, shows effect of different 'network brake' drug combinations on wildtype flies
View article: Figure S2&S3 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Figure S2&S3 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
Figure S2, S3, shows effect of different doses of sorafenib on wing phenotype and cellular pathways in flies
View article: Figure S4&S5 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Figure S4&S5 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
Figure S4, S5, shows drug combinations that restrain or hyperactivate different cellular pathways in flies
View article: Figure S1 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Figure S1 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
Figure S1 shows fly drug screening assay and list of compounds screened
View article: Figure S1 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Figure S1 from Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance Open
Figure S1 shows fly drug screening assay and list of compounds screened
View article: Supplementary Figure Legends 1-5 from Hedgehog Signaling Inhibition Blocks Growth of Resistant Tumors through Effects on Tumor Microenvironment
Supplementary Figure Legends 1-5 from Hedgehog Signaling Inhibition Blocks Growth of Resistant Tumors through Effects on Tumor Microenvironment Open
PDF file - 100K